瑞典类风湿关节炎患者抗TNF治疗后工作能力恢复与丧失的预测因素
该研究基于瑞典生物制剂登记(ARTIS)数据,纳入2006至2009年间首次使用TNF抑制剂的19-62岁RA患者,分别分析基线完全工作能力者(n=1048)与完全丧失工作能力者(n=753)在治疗3年内工作能力变化。结果显示,完全丧失工作能力者中病程<5年者3年内恢复工作能力的概率为35%,病程≥5年者为14%(调整HR 2.1,95%CI 1.4-3.2);基线完全工作能力者中病程不能预测工作能力丧失。
要点
- 完全丧失工作能力的RA患者中,病程<5年者抗TNF治疗后3年恢复工作能力概率为35%,≥5年者为14%。
- 病程<5年者恢复工作能力的调整HR为2.1(95%CI 1.4-3.2),较早治疗与更高恢复概率相关。
- 基线完全工作能力者中,病程不预测工作能力丧失,基线残疾养老金也是恢复工作能力的强预测因素。
核心结论
- 相当比例完全丧失工作能力的RA患者启动抗TNF治疗后恢复工作能力。
- 症状出现5年内启动治疗者3年恢复工作能力的概率是更晚启动者的两倍以上。
- 该效应很大程度上归因于病程对残疾养老金状态的影响。
研究设计与样本
- 基于瑞典生物制剂登记(ARTIS)的队列研究,纳入2006-2009年首次使用TNF抑制剂的19-62岁RA患者。
- 基线完全工作能力组(生物制剂启动前3个月病假/残疾养老金天数为0;n=1048)与完全丧失工作能力组(90天;n=753)。
- 从社会保险局获取病假/残疾养老金天数,采用生存分析及Cox回归估计基线预测因素。
主要发现
- 抗TNF启动后3年内,完全丧失工作能力患者中病程<5年者恢复工作能力概率为35%,病程≥5年者为14%。
- 病程<5年 vs ≥5年的调整HR为2.1(95%CI 1.4-3.2)。
- 基线完全工作能力患者中,病程不预测工作能力丧失。
- 基线残疾养老金也是治疗后恢复工作能力的强预测因素。
临床怎么用
- 对完全丧失工作能力的RA患者,若病程<5年,抗TNF治疗可能带来更高的3年工作能力恢复概率。
- 临床决策时可考虑病程及基线残疾养老金状态对工作能力恢复的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine predictors of work ability gain and loss after anti-tumour necrosis factor (TNF) start, respectively, in working-age patients with rheumatoid arthritis (RA) with a special focus on disease duration. METHODS: Patients with RA, aged 19-62 years, starting their first TNF inhibitor 2006-2009 with full work ability (0 sick leave/disability pension days during 3 months before bio-start; n=1048) or no work ability (90 days; n=753) were identified in the Swedish biologics register (Anti-Rheumatic Treatment In Sweden, ARTIS) and sick leave/disability pension days retrieved from the Social Insurance Agency. Outcome was defined as work ability gain ≥50% for patients without work ability at bio-start and work ability loss ≥50% for patients with full work ability, and survival analyses conducted. Baseline predictors including disease duration, age, sex, education level, employment, Health Assessment Questionnaire, Disease Activity Score 28 and relevant comorbidities were estimated using Cox regression. RESULTS: During 3 years after anti-TNF start, the probability of regaining work ability for totally work-disabled patients was 35% for those with disease duration <5 years and 14% for disease duration ≥5 years (adjusted HR 2.1 (95% CI 1.4 to 3.2)). For patients with full work ability at bio-start, disease duration did not predict work ability loss. Baseline disability pension was also a strong predictor of work ability gain after treatment start. CONCLUSIONS: A substantial proportion of work-disabled patients with RA who start anti-TNF therapy regain work ability. Those initiating treatment within 5 years of symptom onset have a more than doubled 3-year probability of regaining work ability compared with later treatment starts. This effect seems largely due to the impact of disease duration on disability pension status.
引用
- Olofsson T, Petersson IF, Eriksson JK, et al. Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work? Ann Rheum Dis. 2017. PMID: 28073801. doi:10.1136/annrheumdis-2016-210239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。